VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
AFJK
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
AFJKAimei Health Technology Co., Ltd
$27.54$169M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksAFJKFinancials

Aimei Health Technology Co., Ltd (AFJK) Financials

3Y historyFree accessUpdated daily

Net interest income has experienced a sharp 82% year-over-year contraction, falling from $943.5K in 2024Q3 to $107.4K by 2026Q1, reflecting the entity's inability to sustain its interest-bearing asset base.

AFJK Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23
Net Interest Income1.4M1.9M3.62M199.85K
NII Growth %-238.91%-47.59%1709.88%-
Net Interest Margin %11.43%15.66%4.9%0.28%
Interest Income1.4M1.9M3.62M199.85K
Interest Expense0000
Loan Loss Provision0000
Non-Interest Income-1.4M-1.9M-3.62M-199.85K
Non-Interest Income %----
Total Revenue0000
Revenue Growth %0%---
Non-Interest Expense484.33K835.76K1.06M28.46K
Efficiency Ratio----
Operating Income-484.33K-835.76K-1.06M-28.46K
Operating Margin %----
Operating Income Growth %-21.52%-3642.23%-
Pretax Income920.55K1.06M2.55M171.39K
Pretax Margin %----
Income Tax0000
Effective Tax Rate %0%0%0%0%
Net Income920.55K1.06M2.55M171.39K
Net Margin %----
Net Income Growth %-53.54%-58.47%1389.01%-
Net Income (Continuing)920.55K1.06M2.55M171.39K
EPS (Diluted)0.880.170.280.02
EPS Growth %-23.68%-39.29%1373.68%-
EPS (Basic)-0.170.280.02
Diluted Shares Outstanding1.04M4.05M9.03M9.03M

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Going concern liquidity crisis

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Net Interest Income Rapidly Eroding

As reported in financial statements, AFJK's net interest income has experienced a sharp decline, falling from a peak of $943.5K in 2024Q3 to just $107.4K by 2026Q1, representing an 82% year-over-year contraction that highlights the entity's inability to sustain its interest-bearing asset base.

The consistent downward trajectory in net interest income suggests that the underlying capital base is being depleted to fund ongoing administrative overhead. Investors should monitor whether this trend indicates an exhaustion of the entity's ability to generate even minimal interest income before a potential liquidation event.

Net Interest Margin Volatility Persists

Based on the company's quarterly filings, the net interest margin has fluctuated significantly, reaching a low of 0.3% in 2023Q4 and a brief peak of 2.9% in 2025Q4, reflecting the instability inherent in a shell company lacking a stable, long-term asset-liability management strategy.

The erratic NIM behavior appears to be a byproduct of shrinking cash balances rather than active yield management. This volatility suggests that the entity lacks the scale or structural integrity to maintain consistent interest spreads, rendering traditional margin analysis largely irrelevant for this vehicle.

Operational Leverage Remains Non-Existent

According to recent SEC filings, AFJK maintains an efficiency ratio that is effectively unmeasurable due to the absence of operational revenue, underscoring the firm's status as a pre-revenue shell rather than a functioning financial institution with scalable cost structures or meaningful operating leverage.

The lack of revenue generation means that every dollar spent on administrative and professional fees directly erodes the remaining capital. This structure implies that the entity is currently a cost-center with no path to operational efficiency until a business combination is successfully executed.

Liquidity Constraints Threaten Entity Viability

Data from the most recent quarterly reports indicates that the company's cash position has dwindled to $2,929, a figure that warrants further investigation into the entity's ability to meet its ongoing regulatory and listing obligations without immediate external capital support or sponsor intervention.

The extreme scarcity of liquid assets suggests that the company may be facing a critical going concern risk. Investors should be wary that the current financial profile may necessitate dilutive financing or a distressed merger, which could significantly impair the value of existing equity interests.

AFJK — Frequently Asked Questions

Quick answers to the most common questions about buying AFJK stock.

Is Aimei Health Technology Co., Ltd (AFJK) profitable?

Aimei Health Technology Co., Ltd (AFJK) is profitable, generating $1.1M in net income for the fiscal year ending 2025.